These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Clift PF; Townend JN; Bramhall S; Isaac JL Transplantation; 2004 Jun; 77(11):1774-5. PubMed ID: 15201683 [No Abstract] [Full Text] [Related]
4. Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost. Beretta L; Scorza R; Del Papa N; Mazzone A J Rheumatol; 2006 Sep; 33(9):1915-6; author reply 1916. PubMed ID: 16960959 [No Abstract] [Full Text] [Related]
5. Improving the outcome of childhood pulmonary arterial hypertension: the effect of bosentan in the setting of a dedicated pulmonary hypertension clinic. Adatia I J Am Coll Cardiol; 2005 Aug; 46(4):705-6. PubMed ID: 16098439 [No Abstract] [Full Text] [Related]
6. Treatment of pulmonary hypertension secondary to alveolar microlithiasis with Bosentan: a case report. Gialafos EJ; Moyssakis I; Taktikou H; Voteas V; Sfikakis PP Sarcoidosis Vasc Diffuse Lung Dis; 2005 Oct; 22(3):237. PubMed ID: 16315791 [No Abstract] [Full Text] [Related]
7. Ease symptoms of pulmonary hypertension with bosentan. Kupecz D; Berardinelli C Nurse Pract; 2002 Jun; 27(6):51-3. PubMed ID: 12094086 [No Abstract] [Full Text] [Related]
8. [Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension]. Tsareva NA Ter Arkh; 2013; 85(12):127-36. PubMed ID: 24640682 [TBL] [Abstract][Full Text] [Related]
9. Bosentan treatment in an adult with pulmonary hypertension due to patent ductus arteriosus permits surgical repair. Mitropoulos FA; Apostolopoulou SC; Kanakis MA; Rammos S; Anagnostopoulos CE J Heart Lung Transplant; 2007 Dec; 26(12):1345-6. PubMed ID: 18096490 [No Abstract] [Full Text] [Related]
10. [Bosentán, hope or reality for the treatment of pulmonary arterial hypertension]. Callejas Rubio JL; Ortego Centeno N; Benticuaga Martínez MN; de la Higuera Torres-Pujol JM Med Clin (Barc); 2004 Jun; 123(4):158-9, author reply 159. PubMed ID: 15274815 [No Abstract] [Full Text] [Related]
11. Bosentan: a rapidly expanding role in the management of cardio-thoracic diseases. Kapoor S Rheumatol Int; 2008 Nov; 29(1):115. PubMed ID: 18500454 [No Abstract] [Full Text] [Related]
12. Bosentan in mild pulmonary hypertension. van der Plas MN; Duffels MG; Ponse D; Mulder BJ; Bresser P Lancet; 2008 Nov; 372(9651):1730; author reply 1731. PubMed ID: 19013316 [No Abstract] [Full Text] [Related]
13. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Kiakouama L; Cottin V; Etienne-Mastroïanni B; Khouatra C; Humbert M; Cordier JF Eur Respir J; 2010 Jul; 36(1):202-4. PubMed ID: 20595165 [No Abstract] [Full Text] [Related]
14. Bosentan for the treatment of adult pulmonary hypertension. Dwyer N; Kilpatrick D Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507 [TBL] [Abstract][Full Text] [Related]
15. Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome. Ren R; He F; Xiao X Int J Cardiol; 2014 Dec; 177(3):1054-5. PubMed ID: 25465836 [No Abstract] [Full Text] [Related]
16. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension]. MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438 [No Abstract] [Full Text] [Related]
18. Bosentan therapy for pulmonary arterial hypertension. Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289 [TBL] [Abstract][Full Text] [Related]
19. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Foley RJ; Metersky ML Respiration; 2008; 75(2):211-4. PubMed ID: 16293957 [TBL] [Abstract][Full Text] [Related]
20. Bosentan treatment for pulmonary arterial hypertension due to patent ductus arteriosus and Down's syndrome in an infant. He J; Ren Y; Chen Y; Feng Y Int J Cardiol; 2014 Oct; 176(3):e117-8. PubMed ID: 25129297 [No Abstract] [Full Text] [Related] [Next] [New Search]